{
  "trial_id": "NCT00450463",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Histopathological documentation of prostate cancer confirmed in the Laboratory of Pathology at the: National Institutes of Health (NIH) Clinical Center prior to starting this study.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Must have non-metastatic androgen insensitive prostate cancer with a rising PSA (prostatic specific antigen) with castrate levels of testosterone and no evidence of metastatic disease on CT (computed tomography) scan or bone scan.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Life expectancy greater than or equal to 6 months.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "ECOG (Eastern Cooperative Oncology Group) performance status of 0-1.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "No systemic steroid or steroid eye drop use within 2 weeks prior to initiation of experimental therapy.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Hematological eligibility parameters: Granulocyte count greater than or equal to 1,500/mm(3).",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Biochemical eligibility parameters (within 16 days of starting therapy): Hepatic function: Bilirubin less than or equal to 1.5 mg/dl.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "No other active malignancies within the past 3 years (with the exception of non-melanoma skin cancers or carcinoma in situ of the bladder) or life threatening illnesses.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Willing to travel to the NIH for follow-up visits.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "18 years of age or greater.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Able to understand and sign informed consent.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Must agree to use effective birth control (such as a condom) or abstinence during and for a period of 4 months after the last vaccination therapy. Patients must be willing to remain on chemical castration therapy, unless they have had surgical castration.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Patients must have recovered from acute toxicities related to prior therapy or surgery.",
      "label": "met",
      "evidence": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "Patients should have no evidence of being immunocompromised as listed below.",
      "label": "not_met",
      "evidence": "quote"
    },
    {
      "criterion": "Human immunodeficiency virus positivity due to the potential for decreased tolerance and may be at risk for severe side effects.",
      "label": "triggers",
      "evidence": "none"
    },
    {
      "criterion": "Concurrent use of topical steroids (including steroid eye drops) or systemic steroids.",
      "label": "triggers",
      "evidence": "none"
    }
  ],
  "notes": "The patient is a 63-year-old man presenting to the Emergency Department with a history of acute urinary retention in the past 2 days. Abdominopelvic CT scan revealed a large prostate and a bladder filled with urine.",
  "_meta": {
    "topic_id": "60",
    "trial_id": "NCT00450463",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}